Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification

Prior treatment

• Severe concomitant pathology, increasing anesthesiologic and surgical risks, via the desicion of the research physician or conclusion by multidisciplinary team in centers- participants.
• Tumor volume does not technically allow to provide minimally-invasive surgery, based on the conclusion of multidisciplinary experts board team in centers- participants.
• Therapy strategy: observation
  • \-

Other

• 3 and more IDRF + central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more.

• Patients with neurogenic tumors meeting the criteria of groups I-III:
  • Group I
  • low or moderate risk group according to pilot difficulty scoring system (less than 5 points, see supplementary material);
  • no IDRF;
  • Group II:
  • low or moderate risk group according to pilot difficulty scoring system (less than 5 points);
  • patients with any number of IDRFs and without central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more.
  • Group III:
  • 2 and more IDRF + central tumor location and/or tumor extension across the midline;
  • 2 and more IDRF + tumor volume (cm3)/patient height (m) ratio = 28 or more;
  • 2 and more IDRF + 2 and more other risk factors according to pilot difficulty scoring system;
  • 1 IDRF + tumor extension across the midline + tumor volume (cm3)/patient height (m) ratio = 28 or more.
• Age from 0 to 18 years.
• Preoperative imaging (abdominal contrast-enhanced computed tomography (CT), performed no later than 14 days before the planned surgery).
• Indications for surgery based on the decision of multidisciplinary experts board in centers- participants.
• Written voluntary informed consent of the patient and / or his legal representative.